Medida de adherencia al tratamiento en pacientes con hiperuricemia o gota

  1. Esquivel Prados, Elisabeth
  2. García Corpas, José P. 1
  1. 1 Universidad de Granada, España
Revista:
Ars pharmaceutica

ISSN: 2340-9894,  0004-2927

Any de publicació: 2013

Volum: 54

Número: 3

Pàgines: 16-22

Tipus: Article

DIALNET GOOGLE SCHOLAR lock_openAccés obert editor

Altres publicacions en: Ars pharmaceutica

Resum

Aim: To measure the gout medication adherence in patients with hyperuricemia or gout and to determine the factors associated with adherence to anti-gout treatment. Method: Cross-sectional observational study conducted in Pharmacy Gomez Parera, Armilla (Granada). We included patients older than 18 with medical prescription to treat hyperuricemia or gout. Uric acid was measured (Refloton ®) and adherence to treatment by the questionnaire BMQ (The Brief Medication Questionnaire). Performed a multivariate logistic regression analysis to study the relationship between serum uric acid and the various associated factors. Results: We included 19 patients, where 89.5% were men. The mean age was 65.5 (SD: 12.94) years. The average value was 6.03 uricemia (SD 2.06). BMQ as a result it was found that only 10.5% were adherent and anti-gout treatment for each point increase in the count of BMQ increases averaged 2.65 mg / dl blood AU. The variables included explained 64.1% of the variability in the model uricemia. Conclusions: Patients who take medicine for gout or hyperuricemia, have low adherence to therapy and blood AU values are related to the degree of adherence to treatment of these patients.

Referències bibliogràfiques

  • Smith EUR, Díaz-Torné C, Perez-Ruiz F, March LM. Epidemiology of gout: An update. Best Pract. Res. Clin. Rheumatol. diciembre de 2010;24(6):811-27.
  • Kim KY, Ralph Schumacher H, Hunsche E, Wertheimer, AI, Kong SX. A literature review of the epidemiology and treatment of acute gout. Clin. Ther. junio de 2003;25(6):1593-617.
  • Silva L, Miguel ED, Peiteado D, Villalba A, Mola M, Pinto J, et al. Compliance in gout patients. Acta Reum. Port. diciembre de 2010;35(5):466-74.
  • Diet, Alcohol Hyperuricemia and Risk of gout. Gout Cryst. Arthropathies. Elsevier Health Sciences; 2011. p. 374.
  • Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher, HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin. Proc. Mayo Clin. julio de 2006;81(7):925-34.
  • Soriano LC, Rothenbacher D, Choi HK, Rodríguez LAG. Contemporary epidemiology of gout in the UK general population. Arthritis Res. Ther. 3 de marzo de 2011;13(2):R39.
  • Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology. 5 de enero de 2009;48(suppl 2):ii9-ii14.
  • Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res. Ther. 2006;8(Suppl 1):S2.
  • Cebollada J, Gimeno JA. Ácido úrico como factor de riesgo cardiovascular. Hipertens. Riesgo Vasc. abril de 2012;29(2):36-43.
  • Álvarez-Lario B, MacArrón-Vicente J. Is there anything good in uric acid? QJM. 12 de enero de 2011;104(12):1015-24.
  • Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: The framingham study. J. Clin. Epidemiol. 1988;41(3):237-42.
  • Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann. Rheum. Dis. septiembre de 2012;71(9):1490-5.
  • Reach G. Treatment adherence in patients with gout. Joint Bone Spine. octubre de 2011;78(5):456-9.
  • Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res. Ther. 2009;11(2):R46.
  • Dalbeth N, Petrie KJ, House M, Chong J, Leung W, Chegudi, R, et al. Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res. 2011;63(11):1605-12.
  • Osterberg L, Blaschke T. Adherence to Medication. N. Engl. J. Med. 2005;353(5):487-97.
  • Nogués Solán X, Sorli Redó ML, Villar García J. Instrumentos de medida de adherencia al tratamiento. An Med Interna. 2007;(24):138-41.
  • Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ. Couns. junio de 1999;37(2):113-24.
  • Trieste L, Palla I, Fusco F, Tani C, Baldini C, Mosca M, et al. The economic impact of gout: a systematic literature review. Clin. Exp. Rheumatol. agosto de 2012;30 (4 Suppl 73):S145-148.
  • Ben AJ, Neumann CR, Mengue SS. The Brief Medication. Questionnaire and Morisky-Green test to evaluate medication adherence. Rev. Saúde Pública. abril de 2012;46(2):279-89.
  • Dalbeth N, House ME, Horne A, Petrie KJ, McQueen FM, Taylor WJ. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. Bmc Musculoskelet. Disord. 16 de septiembre de 2012;13(1):174.
  • Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr. Opin. Rheumatol. marzo de 2010;22(2):165-72.
  • Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. The Lancet. 17 de abril de 2004;363(9417):1277-81.
Fuente de los datos: Dialnet